Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) have earned a consensus recommendation of “Moderate Buy” from the eleven ratings firms that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and nine have given a buy recommendation to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $41.7778.

Several equities analysts have weighed in on OLMA shares. HC Wainwright raised their target price on Olema Pharmaceuticals from $36.00 to $45.00 and gave the company a “buy” rating in a report on Thursday, December 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Olema Pharmaceuticals in a research note on Thursday, January 22nd. JPMorgan Chase & Co. increased their price objective on Olema Pharmaceuticals from $29.00 to $32.00 and gave the company an “overweight” rating in a report on Tuesday, November 18th. Citigroup raised their price objective on Olema Pharmaceuticals from $21.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, December 12th. Finally, The Goldman Sachs Group boosted their target price on Olema Pharmaceuticals from $26.00 to $38.00 and gave the stock a “buy” rating in a report on Thursday, December 11th.

Olema Pharmaceuticals Stock Down 4.5%

Olema Pharmaceuticals stock opened at $21.55 on Tuesday. The company has a current ratio of 8.03, a quick ratio of 8.03 and a debt-to-equity ratio of 0.01. Olema Pharmaceuticals has a 1-year low of $2.86 and a 1-year high of $36.26. The firm’s fifty day simple moving average is $25.16 and its 200-day simple moving average is $18.15. The company has a market capitalization of $1.48 billion, a P/E ratio of -11.52 and a beta of 1.92.

Insider Activity at Olema Pharmaceuticals

In other news, insider Shawnte Mitchell sold 25,000 shares of Olema Pharmaceuticals stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $24.25, for a total value of $606,250.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Ian T. Clark sold 264,800 shares of the company’s stock in a transaction on Friday, December 19th. The stock was sold at an average price of $29.73, for a total transaction of $7,872,504.00. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 805,501 shares of company stock valued at $23,003,832. 16.36% of the stock is owned by company insiders.

Institutional Investors Weigh In On Olema Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the company. EverSource Wealth Advisors LLC grew its position in shares of Olema Pharmaceuticals by 9,476.9% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,245 shares of the company’s stock valued at $31,000 after purchasing an additional 1,232 shares during the last quarter. Torren Management LLC acquired a new position in shares of Olema Pharmaceuticals during the 4th quarter worth about $44,000. Fideuram Intesa Sanpaolo Private Banking S.P.A. bought a new stake in Olema Pharmaceuticals during the 4th quarter valued at approximately $88,000. Nisa Investment Advisors LLC grew its holdings in Olema Pharmaceuticals by 14.5% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,764 shares of the company’s stock valued at $94,000 after buying an additional 477 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in Olema Pharmaceuticals by 44.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,822 shares of the company’s stock valued at $96,000 after buying an additional 1,169 shares during the last quarter. 91.78% of the stock is currently owned by institutional investors.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.